B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund maintained its stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,511 shares of the company’s stock at the end of the 2nd quarter. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Eli Lilly and were worth $2,923,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Ronna Sue Cohen lifted its stake in shares of Eli Lilly and by 0.4% in the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after purchasing an additional 9 shares during the last quarter. Accredited Investors Inc. lifted its stake in shares of Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in shares of Eli Lilly and by 0.5% in the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after purchasing an additional 17 shares during the last quarter. Northwest Quadrant Wealth Management LLC lifted its stake in shares of Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after purchasing an additional 19 shares during the last quarter. Finally, Oakworth Capital Inc. lifted its stake in shares of Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 75.53% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 990,000 shares of company stock worth $82,949,650. 0.20% of the stock is currently owned by insiders.

Several equities analysts have recently commented on the company. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Leerink Swann lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $93.00 to $90.00 in a research note on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and an average price target of $88.97.

Shares of Eli Lilly and Company (NYSE LLY) opened at 86.36 on Friday. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The stock has a market cap of $91.11 billion, a P/E ratio of 37.37 and a beta of 0.34. The firm’s 50-day moving average price is $84.21 and its 200 day moving average price is $82.27.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Equities research analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is presently 90.04%.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/b-s-pension-fund-trustee-ltd-acting-for-the-british-steel-pension-fund-has-2923000-position-in-eli-lilly-and-company-lly/1642499.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.